Radiopharmaceuticals

RadioMedix & Curium Announce CMS Transitional Pass-Through Status for Detectnet™ (copper Cu 64 dotatate injection)

Retrieved on:

Mittwoch, Dezember 9, 2020

Branches of biology, Radiopharmaceuticals, Chemistry, Physical sciences, Chelating agents, Macrocycles, Neuroendocrinology, G protein-coupled receptors, DOTA-TATE, Copper (64Cu) oxodotreotide, Somatostatin receptor 2, Neuroendocrine tumor

The response to Detectnet in the neuroendocrine community has been tremendous, said Curium CEO, North America, Dan Brague.

Key Points:

The response to Detectnet in the neuroendocrine community has been tremendous, said Curium CEO, North America, Dan Brague.
The recent inclusion in a major Appropriate Use Criteria confirms the clinical utility of Detectnet in the neuroendocrine community, said Ebrahim Delpassand, MD, CEO of RadioMedix.
Detectnet is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients.
Non-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2).

Blue Earth Diagnostics Announces First Patient Doses of PET Imaging Agent rhPSMA-7.3 (18F) in Collaboration with Nucleis Radiopharmaceuticals in Liege, Belgium

Retrieved on:

Dienstag, November 24, 2020

Blue Earth Diagnostics has two Phase 3 studies underway to investigate the use of rhPSMA-7.3 (18F) PET imaging in prostate cancer.

Key Points:

Blue Earth Diagnostics has two Phase 3 studies underway to investigate the use of rhPSMA-7.3 (18F) PET imaging in prostate cancer.
Blue Earth Diagnostics acquired exclusive, worldwide rights to rhPSMA imaging technology from Scintomics in 2018, with an option to therapeutic rights.
Blue Earth Diagnostics is a subsidiary of Bracco Imaging S.p.A., a global leader in diagnostic imaging.
Nucleis Radiopharmaceuticals is a GMP manufacturer and distributor of PET imaging agents located in Liege, Belgium.

GE Healthcare Announces First X-ray AI to Help Assess Endotracheal Tube Placement for COVID-19 Patients

Retrieved on:

Montag, November 23, 2020

Technology, Medical devices, Infectious diseases, Other Technology, Software, Biotechnology, Radiology, Health, Data management, Companies, Radiopharmaceuticals, Industries, Economy of the United States, General Electric, RCA, Schenectady, New York, Thomas Edison, GE Healthcare

GE Healthcare today announced a new artificial intelligence (AI) algorithm to help clinicians assess Endotracheal Tube (ETT) placements, a necessary and important step when ventilating critically ill COVID-19 patients.

Key Points:

GE Healthcare today announced a new artificial intelligence (AI) algorithm to help clinicians assess Endotracheal Tube (ETT) placements, a necessary and important step when ventilating critically ill COVID-19 patients.
Today, clinicians are overwhelmed, experiencing mounting pressure as a result of an ever-increasing number of patients, said Jan Makela, President and CEO, Imaging at GE Healthcare.
GE Healthcare and UC San Francisco co-developed Critical Care Suite 2.0 using GE Healthcares Edison platform, which helps deploy AI algorithms quickly and securely.
GE Healthcare is the $16.7 billion healthcare business of GE (NYSE: GE).

Pediatric Medical Devices Market - Growth, Trends, and Forecast (2020 - 2025)

Retrieved on:

Mittwoch, November 18, 2020

Amersham, GE Healthcare, Magnetic resonance imaging, Radiopharmaceuticals, Medical device

The pediatric medical devices market is expected to grow with a CAGR of nearly 8.7% over the forecast period.

Key Points:

The pediatric medical devices market is expected to grow with a CAGR of nearly 8.7% over the forecast period.
Furthermore, the growing investments in research and development programs by the government to develop the medical infrastructure in the pediatric section is boosting the market growth.
However, the lack of awareness of the pediatric medical devices available is the major drawback of market growth.
Some of the companies which are currently dominating the market are TSE MEDICAL, DAVID, Hamilton Medical, GE Healthcare, Fritz Stephan GmbH, Phoenix Medical Systems, Novonate Inc., Elektro Mag, Trimpeks, Atom Medical Corp.
Reasons to Purchase this report:
ReportLinker is an award-winning market research solution.

Digirad Corporation to Present at Investor Conferences in November

Retrieved on:

Freitag, November 13, 2020

Companies, Amersham, GE Healthcare, Magnetic resonance imaging, Radiopharmaceuticals

Investors can download a PDF copy of the presentation by visiting Digirads Investor Relations section of the website: http://ir.digirad.com/

Key Points:

Investors can download a PDF copy of the presentation by visiting Digirads Investor Relations section of the website: http://ir.digirad.com/
Digirad Corporation is a diversified holding company with three divisions: Healthcare, Building & Construction, and Real Estate & Investments.
Digirad Health designs, manufactures, and distributes diagnostic medical imaging products.Digirad Health operates in three businesses: Diagnostic Services,Mobile Healthcare, and Diagnostic Imaging.
ATRM operates in two businesses: (i) modular building manufacturing and (ii) structural wall panel and wood foundation manufacturing, including building supply retail operations.
KBS, EdgeBuilder and Glenbrook are wholly-owned subsidiaries of ATRM, which is a wholly-owned subsidiary of Digirad.

Lantheus Holdings Announces FDA Clearance for AI-Enabled Automated Bone Scan Index (aBSI) in Prostate Cancer on GE Healthcare’s Xeleris Platform

Retrieved on:

Freitag, November 13, 2020

Lantheus is delighted by the U.S. approval of our digital AI solution for prostate cancer, aBSI, on GE Healthcares platform.

Key Points:

Lantheus is delighted by the U.S. approval of our digital AI solution for prostate cancer, aBSI, on GE Healthcares platform.
The platform offers a fast and reliable alternative to manual interpretation of bone scan images of metastatic prostate cancer.
The aBSI product is vendor neutral stand-alone software as a medical device which calculates the automated bone scan index in Technetium-99m bone scintigraphy.
The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDEs M1|RT Comparison.

Accuray Appoints Renowned Medical Device Industry Executive Jim Dennison as Senior Vice President of Global Quality and Regulatory Affairs

Retrieved on:

Donnerstag, November 12, 2020

Companies, Economy, Industries, Amersham, GE Healthcare, Magnetic resonance imaging, Radiopharmaceuticals, Regulatory affairs, General Electric

SUNNYVALE, Calif., Nov. 12, 2020 /PRNewswire/ --Accuray Incorporated (NASDAQ: ARAY) announced today it has appointed Jim Dennison as its senior vice president of global quality and regulatory affairs, effective immediately.

Key Points:

SUNNYVALE, Calif., Nov. 12, 2020 /PRNewswire/ --Accuray Incorporated (NASDAQ: ARAY) announced today it has appointed Jim Dennison as its senior vice president of global quality and regulatory affairs, effective immediately.
Mr. Dennison is an accomplished quality assurance and regulatory affairs executive with a nearly 15 year tenure at GE Healthcare.
At Accuray, he will lead overall quality, regulatory and government affairs, along with product compliance, reporting to Joshua H. Levine, president and chief executive officer.
Most recently, Mr. Dennison served as senior executive vice president, quality and regulatory affairs at GE Healthcare, managing more than 40 global design and manufacturing sites across 12 GE Healthcare businesses, including imaging.

GE Healthcare, GenesisCare Partner to Tackle Two Biggest Health Burdens Globally, Deliver Improved Cancer and Cardiovascular Care to Patients Around the World

Retrieved on:

Montag, November 9, 2020

Oncology, Health, Hospitals, Radiology, Cardiology, Biotechnology, Amersham, GE Healthcare, Magnetic resonance imaging, Radiopharmaceuticals, Health care, Medicine

GenesisCare recently acquired major U.S. integrated cancer care provider, 21st Century Oncology, increasing access to world-class cancer care for patients across U.S. communities as well as its global network.

Key Points:

GenesisCare recently acquired major U.S. integrated cancer care provider, 21st Century Oncology, increasing access to world-class cancer care for patients across U.S. communities as well as its global network.
"We hope that combining GenesisCare's clinical excellence with GE Healthcare's medical diagnostic innovation and AI capabilities will positively impact millions of cancer and cardiac patients."
Sydney headquartered GenesisCare delivers treatment to people with cancer and heart disease, the two largest disease burdens globally.
We believe that care should be focused on the individual, not the condition, and are proud of our world-class patient satisfaction ratings.

Agreement Signed to Advance Lutetium-177 Isotope Production to Meet Global Demand for Critical Cancer-Fighting Therapies

Retrieved on:

Donnerstag, Oktober 29, 2020

Pharmaceutical, Health, Oncology, Physical sciences, Chemistry, Medicinal radiochemistry, Natural sciences, Radiopharmaceuticals, Lutetium, Isotopes in medicine, Nuclear medicine

The unique international partnership among the three companies brings together a wealth of knowledge in nuclear engineering, operations, and radiopharmaceutical production and development.

Key Points:

The unique international partnership among the three companies brings together a wealth of knowledge in nuclear engineering, operations, and radiopharmaceutical production and development.
Ontario continues to position itself as a world leader in the production of life-saving medical isotopes, said Minister Fedeli.
Processing and global distribution of pharmaceutical grade Lutetium-177 by ITM is enabled through the companys global network of radiopharmaceutical production facilities.
The partnerships primary goal is to guarantee the supply of pharmaceutical grade Lutetium-177 and meet the medical communitys growing demand for this important isotope.

Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2030 - Focus on the Supply Chain Model of Medical Isotope Mo-99 (Tc-99m)

Retrieved on:

Mittwoch, Oktober 21, 2020

Physical sciences, Natural sciences, Chemistry, Medicinal radiochemistry, Radiopharmaceuticals, Medical physics, Medicinal chemistry, Radiochemistry, Technetium-99m, Nuclear medicine, Technetium, Isotopes in medicine

DUBLIN, Oct. 21, 2020 /PRNewswire/ -- The "Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points:

DUBLIN, Oct. 21, 2020 /PRNewswire/ -- The "Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
The 'Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030' report provides a detailed study on the current market landscape and future potential of the companies having the capabilities to manufacture radiopharmaceuticals.
Over the years, medical research teams across the world have gradually tapped into the vast potential of radiopharmaceuticals and nuclear medicines.
A detailed discussion on the supply chain model of medical isotope Mo-99 (Tc-99m), highlighting the main steps of the supply chain, from irradiation of uranium targets in nuclear research reactors to the administration of Tc-99m to patients.